Based on this and our previous experimental evidence [18], we explored the possibility of using ZNF281 expression levels as a predictive marker of resistance to the DNA-damaging agents commonly used as anti-tumour therapies (radio- and chemo-therapies). Here, ZNF281 is linked to neoplasm.